Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 7, 2007, Pages 497-504

  Salamov, German ^a   Holms, Rupert ^b   Bessler, Wolfgang G ^c   Ataullakhanov, Ravshan ^d  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b Medezrin Limited   (United Kingdom)

^c UNIVERSITY OF FREIBURG   (Germany)

^d INSTITUTE OF IMMUNOLOGY   (Russian Federation)

Author keywords

Ezrin; Gepon ; Hepatitis C therapy; Hepatitis C virus; Human ezrin peptide one; Human immunodeficiency virus

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; EZRIN; INTERFERON; LIVER ENZYME; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 34547785016     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296637     Document Type: Article

References (9)

1. Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GT-Pase signalling in leucocytes. Immunology. 2004;112:165-176.
2. Holms R, Attaulakhanov R. HCV Therapy. United States Patent 20060067913, dated 03/30/2006, Application Number 188616
3. Grobarets IP, Voronkova NV,, Lopatina TV, Ivanovskaya NV, Braginsky DM. Experimental application of pharmaceutical Gepon in combination with Recombinant Alpha-Interferon in patients with chronic Hepatitis C. Russ Med J. 2003;11:714-717.
4. Cherednichenko TV, Chaplygina GV, Uchaykin VF. Application of the pharmaceutical Gepon to the treatment of acute and chronic Viral Hepatitis in children. Infect Children. 2003;1:44-47.
5. Cherednichenko TV, Uchaykin VF. Positive influence of pharmaceutical Gepon on the clinical laboratory indices and disbacteriosis of the bowel in children suffering from Viral Hepatitis. Russ Med J. 2003;11:468-471.
6. Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infect Dis. 2004;4:437-444.
7. Winnock M, Salmon-Ceron D, Dabis F, Chene G. Interaction between HIV-1 and HCV infections: towards a new entity?, J Antimicrob Chemother. 2004;53:936-946.
8. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons, N Engl J Med. 2004;351(5):451-459.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalesz-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic Hepatitis C Virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5):438-450.